Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVOR-2: Emrosi in papulopustular rosacea
NCT05343455Phase 3Completed
- Sponsor
- Journey Medical Corporation
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of minocycline hydrochloride modified release (DFD-29) in papulopustular rosacea, sponsored by Journey Medical Corporation. Started Mar 2022; status: completed.
02
Drugs
minocycline hydrochloride modified release (DFD-29)
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT05343455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05343455.